JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.Read Article
Denosumab is effective in osteoporosis when used on schedue, but research suggests that discontinuation leads to rapid reversal of effect; a new observational study has shown that delays in denosumab administration of more than 16 weeks results in an increased vertebral fracture risk,Read Article
Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.Read Article
In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.
This guideline committee included 28Read Article
Data from the Framingham Heart Study has shown that hip fracture incidence has decreased over time, probably resulting from improved lifestyle changes (less smoking and heavy drinking).
The incidence of hip fracture has been shown to be decreasing in the US, presumeably attributeableRead Article
JAMA Internal Medicine reports on a controlled clinical trial of knee osteoarthritis patients wherein meloxicam responses were not significantly or clinically superior to placebo or CBT (after placebo).
Because of the uncertain benefits and safety of long-term NSAIDs,Read Article
Highly purified synthetic trans-capsaicin (CNTX‐4975) injected directly into the joint reduced pain in chronic knee osteoarthritis (OA), data from the open-label phase III VICTORY-3 trial showed.
People with bilateral knee OA pain who received the investigational treatment had lessRead Article